Results 171 to 180 of about 19,854 (197)

Effect of anti-PCSK9 drugs on the association of PCSK9 to LDL

European Atherosclerosis Journal
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that is known to interact with the LDL receptor, thereby promoting its degradation and blunting the uptake of LDL from the circulation. In this context, anti-PCSK9 monoclonal antibodies (mAbs) and siRNAs have been approved for the treatment of hypercholesterolaemia.
Matteucci, Sara, Pravatà, Valentina, Esposito, Francesco Maria, Pirillo, Angela, Grigore, Liliana, Catapano, Alberico Luigi   +5 more
openaire   +1 more source

???????????????? ???????? PCSK9 ?? ?????????????????? ?????????????????????? ?????????????? ???? ?????????????????? ??????????????????????????????????????

2013
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating levels of lowdensity lipoprotein (LDL) particles. PCSK9 acts mainly by enhancing degradation of the LDL receptor in the liver. Several gain-of-function and loss-of-function mutations in the PCSK9 gene have been identified and linked to hypercholesterolemia and ...
openaire   +1 more source

Pushing the envelope with PCSK9

Nature Reviews Drug Discovery, 2021
openaire   +2 more sources

S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway

Cell Reports, 2022
Dianyun Ren, Heshui Wu
exaly  

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36

Circulation, 2021
Liang Hu, Wenlong Yang, Zhifeng Yao
exaly  

Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection

Circulation, 2023
Heng Xu, Jizhang Yu, Jikai Cui
exaly  

PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia

Basic Research in Cardiology, 2020
Xianwei Wang, Meili Liu, Jinghang Zhang   +2 more
exaly  

PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1

Cardiovascular Research, 2020
Zufeng Ding, Naga Venkata K Pothineni, Akshay Goel   +2 more
exaly  

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Proceedings of the National Academy of Sciences of the United States of America, 2008
Maria Frank-Kamenetsky, Norma N Anderson, Akin Akinc   +2 more
exaly  

Binding of PCSK9 to circulating LDL: Effect of PCSK9 monoclonal antibodies on the LDL-bound PCSK9?

Atherosclerosis, 2018
D. De Stefano, A. Baragetti, A. Baragetti, N. Macrì, H. Tavori, S. Fazio, A.L. Catapano   +6 more
openaire   +1 more source